| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
|
Blood
|
2001
|
4.65
|
|
2
|
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
|
N Engl J Med
|
1982
|
3.78
|
|
3
|
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.
|
Blood
|
1999
|
2.97
|
|
4
|
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
|
J Clin Oncol
|
2000
|
2.38
|
|
5
|
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
|
Blood
|
2000
|
2.11
|
|
6
|
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
|
Blood
|
2001
|
2.04
|
|
7
|
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
|
Leukemia
|
2006
|
1.92
|
|
8
|
A clinical trial of anti-idiotype therapy for B cell malignancy.
|
Blood
|
1985
|
1.91
|
|
9
|
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
|
Bone Marrow Transplant
|
2006
|
1.84
|
|
10
|
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.
|
Blood
|
1997
|
1.80
|
|
11
|
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia.
|
Blood
|
1981
|
1.52
|
|
12
|
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.
|
Hybridoma
|
1985
|
1.43
|
|
13
|
Bile secretory apparatus: evidence for a vesicular transport mechanism for proteins in the rat, using horseradish peroxidase and [125I]insulin.
|
Gastroenterology
|
1980
|
1.42
|
|
14
|
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
|
J Immunol
|
1986
|
1.40
|
|
15
|
Infant Airtraq for adult bougie placement.
|
Anaesthesia
|
2014
|
1.39
|
|
16
|
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
|
J Immunol
|
1987
|
1.28
|
|
17
|
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.
|
Blood
|
2001
|
1.24
|
|
18
|
High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
|
Leukemia
|
2005
|
1.22
|
|
19
|
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
|
J Clin Oncol
|
1999
|
1.14
|
|
20
|
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
|
Blood
|
1998
|
1.14
|
|
21
|
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
|
J Clin Oncol
|
1998
|
1.13
|
|
22
|
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas.
|
J Immunol
|
1984
|
1.06
|
|
23
|
Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation.
|
Blood
|
2001
|
1.03
|
|
24
|
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning.
|
Br J Haematol
|
2005
|
1.02
|
|
25
|
Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein.
|
Blood
|
1994
|
1.02
|
|
26
|
Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation.
|
Bone Marrow Transplant
|
2004
|
0.99
|
|
27
|
Clinical status and optimal use of rituximab for B-cell lymphomas.
|
Oncology (Williston Park)
|
1998
|
0.98
|
|
28
|
Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting.
|
Blood
|
2000
|
0.98
|
|
29
|
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
|
Bone Marrow Transplant
|
2001
|
0.97
|
|
30
|
The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.
|
J Immunol
|
1981
|
0.96
|
|
31
|
Can the 'two-bag test' detect leaks?
|
Anaesthesia
|
2013
|
0.94
|
|
32
|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
|
Bone Marrow Transplant
|
2011
|
0.93
|
|
33
|
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.
|
J Clin Pharmacol
|
2013
|
0.93
|
|
34
|
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
|
Ann Oncol
|
2009
|
0.90
|
|
35
|
Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation.
|
Blood
|
2000
|
0.89
|
|
36
|
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
|
Clin Cancer Res
|
2000
|
0.87
|
|
37
|
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.
|
J Clin Oncol
|
1996
|
0.86
|
|
38
|
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
|
Blood
|
2001
|
0.86
|
|
39
|
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
|
Bone Marrow Transplant
|
2001
|
0.85
|
|
40
|
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
|
Leukemia
|
2005
|
0.84
|
|
41
|
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
|
Biol Blood Marrow Transplant
|
1997
|
0.83
|
|
42
|
Prilocaine 3% is superior to a mixture of bupivacaine and lignocaine for peribulbar anaesthesia.
|
Br J Anaesth
|
1996
|
0.82
|
|
43
|
Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow.
|
Blood
|
1997
|
0.80
|
|
44
|
Follicular lymphoma: a model of lymphoid tumor progression in man.
|
Ann Oncol
|
1991
|
0.79
|
|
45
|
Comparison of two flow cytometric methods enumerating CD4 T cells and CD8 T cells.
|
Cytometry
|
1998
|
0.79
|
|
46
|
Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century.
|
Transplant Proc
|
2000
|
0.79
|
|
47
|
Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century.
|
Front Biosci
|
2001
|
0.77
|
|
48
|
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.
|
Bone Marrow Transplant
|
2007
|
0.77
|
|
49
|
Non-myeloablative hematopoietic stem cell transplantation.
|
Transfus Clin Biol
|
2001
|
0.76
|
|
50
|
Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry.
|
Blood
|
1999
|
0.76
|
|
51
|
Antibody therapy has arrived. Now where does it fit?
|
Ann Oncol
|
1999
|
0.75
|
|
52
|
Evaluation of airway equipment: man or manikin?
|
Anaesthesia
|
2011
|
0.75
|
|
53
|
Is oxygen a friend or foe in the peri-operative period?
|
Anaesthesia
|
2013
|
0.75
|
|
54
|
Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation.
|
Transpl Immunol
|
1999
|
0.75
|
|
55
|
The thymus is typically small at 1 year after autologous or allogeneic T-cell-replete hematopoietic cell transplantation into adults.
|
Bone Marrow Transplant
|
2004
|
0.75
|